The cluster of open-market purchases by the CEO and two directors immediately after a revenue beat and material acquisition announcement suggests insider conviction in the near-term outlook. Monitor the Heron deal closing and REZZAYO sNDA decision in Q1 2027 as catalysts.
Drugs in focus
CRMD drug pipeline →rezafungin
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
- Next catalyst
- NDA filing · 2026
What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three CorMedix insiders, including CEO Joseph Todisco, made open-market purchases totaling $565K in the week following the Q3 2026 earnings release and the announced Heron asset acquisition. The CEO's $391K purchase is the largest, representing about 0.15% of market cap, and signals confidence after revenue beat and narrowed guidance.
Key Financial Metrics
Key Facts
- CEO Joseph Todisco purchased 80,000 shares at $4.89 for $391K on 2026-11-13
- Director Myron Kaplan purchased 25,000 shares at $4.88 for $122K on 2026-11-16
- Director Steven Lefkowitz purchased 11,500 shares at $4.53 for $52K on 2026-11-18
- Total insider purchases of $565K represent 0.15% of $371M market cap
- Q3 2026 consolidated revenue of $54.5M beat consensus of $51.2M
- Company maintains FY2026 revenue guidance of $325-$345M and narrowed adjusted EBITDA guidance
- Pending Heron Therapeutics asset acquisition expected to close Q1 2027
- FDA accepted sNDA for REZZAYO prophylaxis indication with PDUFA in Q1 2027
Financial Impact
Insider purchases of $565K (0.15% of market cap) by CEO and two directors
Risk Factors
- Post-TDAPA DefenCath pricing headwinds continue; 2027 DefenCath guidance suspended
- Heron acquisition requires stockholder approval and regulatory clearance
- Revenue declined 48% YoY from $104.3M to $54.5M due to TDAPA transition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CRMD-1795199694745 |
Track record
24 reports on CRMD
9 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 12 of 14 went positive at some point.
Filters
- Nov 20, 20261d ago Insider Cluster Bullish 5/10 Viewing Entry $5.28 Now $5.27 −0.09% settles Nov 30
- Nov 18, 20263d ago Insider Cluster Bullish 4/10 Entry $5.08 Now $5.27 +3.74% settles Nov 27
- Nov 13, 20268d ago DEFA14A / 8-K Bearish 6/10 Entry $4.82 Now $5.27 −9.34% settles Nov 23
- Nov 12, 202610d ago Press Release Bearish 5/10 Entry $4.84 to $5.08 Now $5.27 −8.88% ▼ −4.96% −10.41% vs SPY
- Nov 10, 202611d ago DEFA14A Neutral 6/10 Entry $5.30 to $4.50 Now $5.27 −0.57% ▼ −15.09% −11.20% vs SPY
- Nov 10, 202611d ago 8-K Bullish 7/10 Entry $5.30 to $4.50 Now $5.27 −0.57% ▼ −15.09% −11.20% vs SPY
- Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $5.27 −3.66% ▼ −11.88% −10.19% vs SPY
- Nov 9, 202612d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $5.27 −3.66% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202619d ago 8-K Neutral 5/10 No price data
- Nov 2, 202620d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $5.27 −2.23% ▲ +1.48% +1.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers